Alex G. Howarth - 01 Nov 2021 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: Chief Financial Officer
Signature: /s/ Brian J. Lynch, As attorney-in-fact for Reporting Person
Issuer symbol: MDGL
Transactions as of: 01 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 03 Nov 2021, 16:26:32 UTC
Previous filing: 19 May 2021
Next filing: 24 Feb 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MDGL	Stock Option (Right to Buy)	Award	$0	+5,000		$0.000000	5,000	01 Nov 2021	Common Stock	5,000	$81.95	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 25% of the shares on the first anniversary of the date of grant (11/1/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. This option was granted under our 2015 stock plan at a regularly scheduled meeting of the Compensation Committee of our Board of Directors on November 1, 2021.

Content

The option vests as to 25% of the shares on the first anniversary of the date of grant (11/1/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. This option was granted under our 2015 stock plan at a regularly scheduled meeting of the Compensation Committee of our Board of Directors on November 1, 2021.